Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-05-14 Purchase | 2024-05-15 07:19 am | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 36,300 | $5.57 | $202,191 | 266,744 (Direct) | View |
| 2022-12-15 Sale | 2022-12-19 4:55 pm | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 5,700 | $10.9 | $62,130 | 163,966 (Direct) | View |
| 2021-11-23 Purchase | 2021-11-24 6:35 pm | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 35,258 | $12.48 | $440,020 | 93,719 (Direct) | View |
| 2020-08-11 Purchase | 2020-08-12 4:31 pm | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 54,000 | $4.08 | $220,320 | 54,000 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-12-14 Tax Withholding | 2024-12-17 4:06 pm | N/A N/A | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 7,890 | $7.53 | 259,628 (Direct) | View |
| 2023-12-19 Tax Withholding | 2023-12-20 4:35 pm | N/A N/A | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 2,482 | $6.05 | 227,444 (Direct) | View |
| 2023-12-14 Tax Withholding | 2023-12-18 4:37 pm | N/A N/A | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 5,475 | $6.43 | 388,426 (Direct) | View |
| 2023-12-14 Option Award | 2023-12-18 4:37 pm | 2024-12-14 2033-12-14 | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 192,500 | $0 | 388,426 (Direct) | View |
| 2022-12-19 Option Award | 2022-12-21 4:32 pm | 2023-12-19 2032-12-19 | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 192,500 | $0 | 356,466 (Direct) | View |
| 2021-12-14 Option Award(A) | 2022-01-13 4:40 pm | N/A N/A | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 75,000 | $0 | 168,719 (Direct) | View |
| 2021-12-14 Option Award | 2021-12-16 4:59 pm | 2022-12-14 2031-12-14 | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 279,000 | $0 | 372,719 (Direct) | View |
| 2020-12-15 Option Award | 2020-12-17 4:23 pm | 2021-12-15 2030-12-15 | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 332,500 | $0 | 332,500 (Direct) | View |
| 2020-04-30 Option Award | 2020-05-04 4:08 pm | 2021-04-30 2020-04-30 | BIOCRYST PHARMACEUTICALS INC | BCRX | Doyle Anthony Chief Financial Officer | 600,000 | $0 | 600,000 (Direct) | View |